Both the ImmuSAFE™ COVID and ImmuSAFE™ COVID+ tests enable high-throughput fully quantitative screening of total immunoglobulin and IgG:IgM ratios towards multiple SARS-CoV-2 antigens, antigens from 5 other Coronaviruses including SARS, MERS as well as Influenza A and B HA antigen subtypes. All viral antigens on the ImmuSAFE™ biochips were expressed using KREX, which ensures that the proteins on the biochip are correctly folded which is critical for maximising true positive results.
By measuring antibodies to multiple viral antigens in a fully quantitative manner, ImmuSAFE™ results are able to determine both the stage of infection as well as the level of antibodies, down to picogram level sensitivity. This is important to determine whether or not an individual has a protective level of antibodies.
In addition to this, as more than 90% of individuals referred to hospitals with suspected COVID-19 actually have flu, the ImmuSAFE™ tests will results are far more likely to be accurate as it also includes multiple Influenza A and B antigens to determine whether an individual has been infected with COVID-19.
